PE20190656A1 - Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 - Google Patents

Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Info

Publication number
PE20190656A1
PE20190656A1 PE2019000282A PE2019000282A PE20190656A1 PE 20190656 A1 PE20190656 A1 PE 20190656A1 PE 2019000282 A PE2019000282 A PE 2019000282A PE 2019000282 A PE2019000282 A PE 2019000282A PE 20190656 A1 PE20190656 A1 PE 20190656A1
Authority
PE
Peru
Prior art keywords
malt1
inhibitors
pyridine compounds
tiazolo
compounds replaced
Prior art date
Application number
PE2019000282A
Other languages
English (en)
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20190656A1 publication Critical patent/PE20190656A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Referido a compuestos de tiazolo-piridina sustituida, de formula (I), en el que R1 se selecciona de H, halogeno, ciano, entre otros; R2 se selecciona de alquilo, alquilo sustituido, cicloalquilo, entre otros; R3 se selecciona de heteroarilo, heteroarilo sustituido, arilo, entre otros. Un compuesto seleccionado es 1-(5-cloro-6-metoxipiridin-3-il)-3-(7-ciclopropil-2-metiltiazolo[5,4-b]piridin-6-il)urea. Ademas, se refiere a su uso como inhibidores de MALT1 en el tratamiento de enfermedades o trastornos inflamatorios y autoinmunes, como el cancer; metodos para sintetizar dichos compuestos y composiciones farmaceuticas que los contiene.
PE2019000282A 2016-07-29 2017-07-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 PE20190656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29

Publications (1)

Publication Number Publication Date
PE20190656A1 true PE20190656A1 (es) 2019-05-08

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000282A PE20190656A1 (es) 2016-07-29 2017-07-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
US11427556B2 (en) * 2017-11-17 2022-08-30 Hepagene Therapeutics (HK) Limited Urea derivatives as inhibitors of ASK1
ES2966457T3 (es) * 2018-06-18 2024-04-22 Janssen Pharmaceutica Nv Derivados de pirazol como inhibidores de MALT1
CN112601747B (zh) * 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
IL303962A (en) * 2018-11-28 2023-08-01 Takeda Pharmaceuticals Co The tricyclic compound
CN113677674A (zh) * 2019-04-11 2021-11-19 詹森药业有限公司 含有吡啶环的作为malt1抑制剂的衍生物
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
CN114945571A (zh) * 2019-12-27 2022-08-26 薛定谔公司 环状化合物及其使用方法
JPWO2021241611A1 (es) 2020-05-27 2021-12-02
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2023192506A1 (en) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
WO2003090746A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
US9051595B2 (en) 2007-06-01 2015-06-09 University Of Lausanne Malt1 specific cleavage in assay and screening method
US8309523B2 (en) * 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
CA2842976A1 (en) * 2011-07-26 2013-01-31 Grunenthal Gmbh Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
ES2716276T3 (es) 2011-08-02 2019-06-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Inhibición selectiva de proteasa MALT1 mediante derivados de fenotiazina
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
WO2014074815A1 (en) 2012-11-09 2014-05-15 Melnick Ari Small molecule inhibitors of malt1
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
US9718811B2 (en) 2013-06-26 2017-08-01 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (S)-enantiomer of mepazine
WO2015110406A1 (en) 2014-01-21 2015-07-30 Helmholtz Zentrum München Means and methods for detecting activated malt1
CN106170489B (zh) * 2014-05-28 2019-05-03 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
MX2018005390A (es) 2015-11-13 2018-08-16 Novartis Ag Nuevos derivados de pirazolo pirimidina.
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
PH12019500214A1 (en) 2019-10-28
US20190275012A9 (en) 2019-09-12
AU2017302182A1 (en) 2019-03-07
MX2019001132A (es) 2019-12-16
AU2017302182B2 (en) 2021-11-04
RU2019104890A3 (es) 2020-08-31
JP2019522035A (ja) 2019-08-08
SG11201900745VA (en) 2019-02-27
KR20190033607A (ko) 2019-03-29
CA3032334A1 (en) 2018-02-01
US20190160045A1 (en) 2019-05-30
DOP2019000020A (es) 2019-04-30
CN110312724A (zh) 2019-10-08
CL2019000221A1 (es) 2019-06-07
IL289474A (en) 2022-02-01
WO2018020474A1 (en) 2018-02-01
RU2019104890A (ru) 2020-08-31

Similar Documents

Publication Publication Date Title
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EA201691302A1 (ru) Новые гетероциклические соединения
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
PE20211246A1 (es) Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN